5 Key Takeaways

• 1

  A clinical trial in Denmark found that high-normal potassium levels reduced adverse outcomes in patients with implantable cardioverter-defibrillators.

• 2

  Over a median follow-up of nearly 40 months, 23% of patients in the high-normal potassium group reached the primary outcome compared to 29% in the standard care group.

• 3

  The intervention group had lower rates of appropriate ICD therapy, unplanned hospitalizations for arrhythmia or heart failure, and death from any cause.

• 4

  The trial enrolled 1,200 patients with baseline potassium levels of 4.3 mmol/L or less, targeting levels between 4.5 and 5.0 mmol/L.

• 5

  Safety monitoring revealed no treatment-related deaths, but hospitalizations due to electrolyte issues occurred in both groups.